We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

The upcoming report from Moderna (MRNA) is expected to reveal quarterly loss of -$2.99 per share, indicating an increase of 10.2% compared to the year-ago period. Analysts forecast revenues of $127.17 ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine. After experiencing remarkable growth during the pandemic with its groundbreaking ...

An explosive phase of growth may be ahead thanks to several potential product launches. A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA).

It also intends to present data from the P304 study at a future medical meeting. MRNA Stock Price Performance Post the above news, shares of Moderna rose nearly 2% yesterday.

That surely came as a relief to Moderna investors, since the company's latest stock-rattling news was its withdrawal of a Food and Drug Administration application for a combination COVID-19/flu ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about MRNA stock here.